glp-1 receptor agonist blood pressure reduction Mechanisms of action of GLP-1RA Endogenous Activation of Glucagon-Like Peptide-1

Reduced inflammation normalizes endometrial receptivity by rebalancing local estrogen and progesterone signaling, which supports implantation

Emerging evidence suggests a potential association of altered levels of acylcarnitines (ACs), which are involved in mitochondrial fatty acids -oxidation, with insulin resistance, cardiovascular and neurodegenerative diseases [6,7,8,9]

Moreover, in light of the growing evidence demonstrating the benefits of incretin-based therapies on both metabolic health and cardiovascular diseases, regulatory agencies such as the Food Drug Administration (FDA) and the European Medicines Agency (EMA) have approved their use for type 2 diabetes, reduction of cardiovascular risk and for chronic weight management in patients with morbid obesity [5,6,7,8]

This creates a domino effect of susceptibility to debilitating chronic ailments in millions of children and their future offspring